Y-mAbs Therapeutics Preparing for Notable Investor Conferences
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) is gearing up to participate in key investor conferences this October. This commercial-stage biopharmaceutical company is dedicated to developing cutting-edge cancer treatments, primarily through novel radioimmunotherapy and antibody-based therapeutic approaches. The management team has scheduled appearances that highlight their innovative therapies and strategic objectives.
Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit
On Tuesday, October 8, 2024, Y-mAbs will take part in the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit. The event kicks off at 9:30 a.m. ET and features a panel discussion titled "The Next Wave of TRTs – Targets, Targeting Technologies and Isotopes." This dialogue promises to address the leading advancements in targeted therapies, fostering important discussions among industry leaders and investors alike.
Key Presentation Details
This summit is a prime opportunity for Y-mAbs to showcase its groundbreaking work in cancer treatment. The panel will explore emerging trends and technologies in targeted radiopharmaceuticals, emphasizing how Y-mAbs' unique approaches can reshape cancer care.
BMO Oncology Summit
Later on the same day, at 3:00 p.m. ET, Y-mAbs will also feature at the BMO Oncology Summit. This segment will include a fireside chat under the caption "Shifting the Antibody Paradigm." Here, the discussion is anticipated to revolve around how the company is innovating and redefining the landscape of antibody treatments.
Topics of Discussion
The conversation at the BMO Oncology Summit will provide insights into Y-mAbs’ strategic direction and the future of its product pipeline. The engagements at both conferences serve as an excellent platform for connecting with investors who are keen on the latest breakthroughs in oncology.
About Y-mAbs
Y-mAbs Therapeutics is at the forefront of biopharmaceutical innovation, especially in cancer therapy. The company has developed a remarkable range of therapeutic products, leveraging its proprietary Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT) and bispecific antibodies created via the Y-BiClone platform. Their flagship product, DANYELZA® (naxitamab-gqgk), holds the distinction of being the first FDA-approved therapy for relapsed or refractory high-risk neuroblastoma. This landmark approval highlights Y-mAbs' commitment to enhancing treatment options for patients suffering from challenging cancer forms.
Investor Engagement
The investor relations team at Y-mAbs is enthusiastic about the conversations that will unfold during these events. Engaging with investors helps to strengthen relationships and provides essential insights into the expectations and desires of the investment community.
Conclusion
Y-mAbs is clearly positioning itself as a leader in the oncology space. Its participation in these significant investor conferences showcases its commitment to transparency and engagement with stakeholders. The innovative therapies developed by Y-mAbs are paving the way for a promising future in cancer treatment.
Frequently Asked Questions
1. What is Y-mAbs Therapeutics known for?
Y-mAbs Therapeutics is known for its innovative cancer therapies, focusing on radioimmunotherapy and antibody-based treatments.
2. When will Y-mAbs participate in the conferences?
Y-mAbs will participate in two conferences on October 8, 2024.
3. What are the names of the conferences Y-mAbs will attend?
Y-mAbs will attend the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit and the BMO Oncology Summit.
4. What is DANYELZA®?
DANYELZA® (naxitamab-gqgk) is Y-mAbs' FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma.
5. How can investors contact Y-mAbs?
Investors can contact Y-mAbs through Courtney Dugan, VP of Investor Relations, via email at cdu@ymabs.com.
